Dominic J. Abrams

Dominic J. Abrams

Auto-generated profile, based on publicly available information

Dominic J. Abrams

Center for Cardiovascular Genetics, Boston Children’s Hospital, MA (D.A.).

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Heart Rhythm
Verified
Journal Article
Closed access
JTJeffrey A. Towbin
Jeffrey A. Towbin
WMWilliam J. McKenna
William J. McKenna
DADominic J. Abrams
Dominic J. Abrams
MAMichael J. Ackerman
Michael J. Ackerman
HCHugh Calkins
Hugh Calkins
WZWojciech Zareba
Wojciech Zareba

12 July 2013 in EP Europace
Verified
Journal Article
Open access
PDF file
JBJosep Brugada
Josep Brugada
NBNico Blom
Nico Blom
GSGeorgia Sarquella-Brugada
Georgia Sarquella-Brugada
CBCarina Blomstrom-Lundqvist
Carina Blomstrom-Lundqvist
JDJohn Deanfield
John Deanfield
EREric Rosenthal
Eric Rosenthal
In children with structurally normal hearts, the mechanisms of arrhythmias are usually the same as in the adult patient. Some arrhythmias are particularly associated with young age and very rarely seen in adult patients. Arrhythmias in structural heart disease may be associated either with the underlying abnormality or result from surgical intervention. Chronic haemodynamic stress of congenital heart disease (CHD) might create an electrophysiological and anatomic substrate highly favourable for re-entrant arrhythmias. As a general rule, prescription of antiarrhythmic drugs requires a clear diagnosis with electrocardiographic documentation of a given arrhythmia. Risk–benefit analysis of drug therapy should be considered when facing an arrhythmia in a child. Prophylactic antiarrhythmic drug therapy is given only to protect the child from recurrent supraventricular tachycardia during this time span until the disease will eventually cease spontaneously. In the last decades, radiofrequency catheter ablation is progressively used as curative therapy for tachyarrhythmias in children and patients with or without CHD. Even in young children, procedures can be performed with high success rates and low complication rates as shown by several retrospective and prospective paediatric multi-centre studies. Three-dimensional mapping and non-fluoroscopic navigation techniques and enhanced catheter technology have further improved safety and efficacy even in CHD patients with complex arrhythmias. During last decades, cardiac devices (pacemakers and implantable cardiac defibrillator) have developed rapidly. The pacing generator size has diminished and the pacing leads have become progressively thinner. These developments have made application of cardiac pacing in children easier although no dedicated paediatric pacing systems exist.

20 March 2018 in EP Europace
Verified
Journal Article
Closed access
PDF file
AHAntonio Hernández-Madrid
Antonio Hernández-Madrid
TPThomas Paul
Thomas Paul
DADominic Abrams
Dominic Abrams
PAPeter F Aziz
Peter F Aziz
NBNico A Blom
Nico A Blom
ADAnne Dubin
Anne Dubin
The population of patients with congenital heart disease (CHD) is continuously increasing with more and more patients reaching adulthood. A significant portion of these young adults will suffer from arrhythmias due to the underlying congenital heart defect itself or as a sequela of interventional or surgical treatment. The medical community will encounter an increasing challenge as even most of the individuals with complex congenital heart defects nowadays become young adults. Within the past 20 years, management of patients with arrhythmias has gained remarkable progress including pharmacological treatment, catheter ablation, and device therapy. Catheter ablation in patients with CHD has paralleled the advances of this technology in pediatric and adult patients with structurally normal hearts. Growing experience and introduction of new techniques like the 3D mapping systems into clinical practice have been particularly beneficial for this growing population of patients with abnormal cardiac anatomy and physiology. Finally, device therapies allowing maintanence of chronotropic competence and AV conduction, improving haemodynamics by cardiac resynchronization, and preventing sudden death are increasingly used. For pharmacological therapy, ablation procedures, and device therapy decision making requires a deep understanding of the individual pathological anatomy and physiology as well as detailed knowledge on natural history and long-term prognosis of our patients. Composing expert opinions from cardiology and paediatric cardiology as well as from non-invasive and invasive electrophysiology this position paper was designed to state the art in management of young individuals with congenital heart defects and arrhythmias.

20 October 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DBDiana C. Blaydon
Diana C. Blaydon
PBPaolo Biancheri
Paolo Biancheri
WDWei-Li Di
Wei-Li Di
VPVincent Plagnol
Vincent Plagnol
RCRita M. Cabral
Rita M. Cabral
DKDavid Kelsell
David Kelsell
We performed genetic and immunohistochemical studies in a sister and brother with autosomal recessive neonatal inflammatory skin and bowel lesions. The girl died suddenly at 12 years of age from parvovirus B19–associated myocarditis; her brother had mild cardiomyopathy. We identified a loss-of-function mutation in ADAM17, which encodes a disintegrin and metalloproteinase 17 (also called tumor necrosis factor α [TNF-α]–converting enzyme, or TACE), as the probable cause of this syndrome. Peripheral-blood mononuclear cells (PBMCs) obtained from the brother at 17 years of age showed high levels of lipopolysaccharide-induced production of interleukin-1β and interleukin-6 but impaired release of TNF-α. Despite repeated skin infections, this young man has led a relatively normal life. (Funded by Barts and the London Charity and the European Commission Seventh Framework Programme.)

1 June 2015 in Circulation
Verified
Journal Article
Closed access
GFGaetano Maria De Ferrari
Gaetano Maria De Ferrari
VDVeronica Dusi
Veronica Dusi
CSCarla Spazzolini
Carla Spazzolini
JBJ. Martijn Bos
J. Martijn Bos
DADominic J. Abrams
Dominic J. Abrams
Peter J. SchwartzPeter J. Schwartz
Peter J. Schwartz
Background—: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disorder causing life-threatening arrhythmias whenever sympathetic activity increases. β-Βlockers are the mainstay of therapy; when they fail, implantable cardioverter-defibrillators (ICDs) are used but often cause multiple shocks. Preliminary results with flecainide appear encouraging. We proposed left cardiac sympathetic denervation (LCSD) as useful additional therapy, but evidence remains anecdotal. Methods and Results—: We report 63 patients with CPVT who underwent LCSD as secondary (n=54) or primary (n=9) prevention. The median post-LCSD follow-up was 37 months. The 9 asymptomatic patients remained free of major cardiac events. Of the 54 patients with prior major cardiac events either on (n=38) or off (n=16) optimal medical therapy, 13 (24%) had at least 1 recurrence: 0 patients had an aborted cardiac arrest, 2 patients had syncope only, 10 patients had ≥1 appropriate ICD discharges, and 1 patient died suddenly. The 1- and 2-year cumulative event-free survival rates were 87% and 81%. The percentage of patients with major cardiac events despite optimal medical therapy (n=38) was reduced from 100% to 32% ( P <0.001) after LCSD, and among 29 patients with a presurgical ICD, the rate of shocks dropped by 93% from 3.6 to 0.6 shocks per person per year ( P <0.001). Patients with an incomplete LCSD (n=7) were more likely to experience major cardiac events after LCSD (71% versus 17%; P <0.01) than those with a complete LCSD. Conclusions—: LCSD is an effective antifibrillatory intervention for patients with CPVT. Whenever syncope occurs despite optimal medical therapy, LCSD could be considered the next step rather than an ICD and could complement ICDs in patients with recurrent shocks.

25 April 2019 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
KAKaryn M. Austin
Karyn M. Austin
MTMichael A. Trembley
Michael A. Trembley
SCStephanie F. Chandler
Stephanie F. Chandler
SSStephen P. Sanders
Stephen P. Sanders
JSJeffrey E. Saffitz
Jeffrey E. Saffitz
WPWilliam Pu
William Pu